EUROPEAN POSITION PAPER ON RHINOSINUSITIS AND NASAL POLYPIS 2020

All topics from EPOS2012 will be revised and updated based on the latest research and evidence. Areas that EPOS2020 will explore in more detail than in previous guidelines are in particular treatment modalities especially with biologicals, need reevaluation in terms of current treatment algorithms. The EPOS 2020 guideline will apply to the adult and pediatric patient population with ARS (viral / common cold, post-viral, bacterial), CRSsNP and CRSwNP. It will furthermore be applicable to patients with associated conditions, such as allergic rhinitis, asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), severe upper airway disease and rare diseases including primary ciliary dyskinesia (PCD), cystic fibrosis, vasculitis and immune deficiencies. EPOS2020 will also address patients with associated symptoms, such as facial pain / pressure, sleep disorders, smell disorders and odontogenic problems, many of which are principal symptoms in the diagnosis of rhinosinusitis.

Patient involvement will be a defining element of EPOS2020, and this is reflected by the inclusion of key patient representatives in the development group, along with a dissemination strategy which will target users beyond the immediate clinical sphere. The initiatives started within EUFOREA that will find a solid base in EPOS2020 and will help to better inform patients and further empower them to seek optimal help in the management of their disease (32-34). The position paper will provide guidelines for relevant government bodies, national and international drug agencies [e.g. the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA] and scientific societies, particularly regarding the use of terminology, definitions and classification for clinical trials.

Patient involvement will be a defining element of EPOS2020, and this is reflected by the inclusion of key patient representatives in the development group, along with a dissemination strategy which will target users beyond the immediate clinical sphere. The initiatives started within EUFOREA that will find a solid base in EPOS2020 and will help to better inform patients and further empower them to seek optimal help in the management of their disease (32-34). The position paper will provide guidelines for relevant government bodies, national and international drug agencies [e.g. the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the USA] and scientific societies, particularly regarding the use of terminology, definitions and classification for clinical trials.